MCID: DYS014
MIFTS: 52

Dyspepsia

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyspepsia

MalaCards integrated aliases for Dyspepsia:

Name: Dyspepsia 12 44 15
Indigestion 12 43 15
Dyspepsia, Indigestion 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2321
ICD10 33 K30 R10.13
MeSH 44 D004415
NCIt 50 C26756
SNOMED-CT 68 87548005
UMLS 73 C0013395

Summaries for Dyspepsia

MedlinePlus : 43 Nearly everyone has had indigestion at one time. It's a feeling of discomfort or a burning feeling in your upper abdomen. You may have heartburn or belch and feel bloated. You may also feel nauseated, or even throw up. You might get indigestion from eating too much or too fast, eating high-fat foods, or eating when you're stressed. Smoking, drinking too much alcohol, using some medicines, being tired, and having ongoing stress can also cause indigestion or make it worse. Sometimes the cause is a problem with the digestive tract, like an ulcer or GERD. Avoiding foods and situations that seem to cause it may help. Because indigestion can be a sign of a more serious problem, see your health care provider if it lasts for more than two weeks or if you have severe pain or other symptoms. Your health care provider may use x-rays, lab tests, and an upper endoscopy to diagnose the cause. You may need medicines to treat the symptoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Dyspepsia, also known as indigestion, is related to gastroparesis and irritable bowel syndrome. An important gene associated with Dyspepsia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Esomeprazole and Mirtazapine have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Indigestion, also known as dyspepsia, is a condition of impaired digestion. Symptoms may include upper... more...

Related Diseases for Dyspepsia

Diseases related to Dyspepsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 31.1 CCK GHRL HTR3A
2 irritable bowel syndrome 31.0 CCK HTR3A SLC6A4 TRPV1
3 stomach disease 30.5 TRPV1 SST PTGS2 PTGS1 HRH2 GHRL
4 anxiety 30.3 CYP2C19 HTR1A HTR3A SLC6A4
5 peptic ulcer disease 30.3 CXCL8 CYP2C19 GHRL HRH2 PTGS2
6 bile reflux 30.1 CCK PTGS2
7 eating disorder 30.1 CCK GHRL SLC6A4
8 gallbladder disease 30.0 CCK CCKAR SST
9 diarrhea 30.0 CCK HTR3A SST TRPV1
10 duodenogastric reflux 30.0 CCK SST
11 duodenal ulcer 30.0 CCK CXCL8 CYP2C19 HRH2 SST
12 gastritis 30.0 CXCL8 GHRL HRH2 PGC PTGS2
13 constipation 29.9 CCK HTR3A SLC6A4 SST
14 cholelithiasis 29.9 CCK CCKAR SST
15 peptic esophagitis 29.8 CXCL8 CYP2C19 HRH2
16 esophagitis 29.7 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
17 gastroesophageal reflux 29.6 TRPV1 PTGS2 PTGS1 HRH2 GHRL CYP2C19
18 atrophic gastritis 29.5 CXCL8 GHRL PGC SST
19 disease of mental health 29.5 CCK HTR1A SLC6A4 TRPV1
20 panic disorder 29.3 CCK CCKAR HTR1A HTR3A SLC6A4
21 major depressive disorder 29.3 CYP2C19 GNB3 HTR1A HTR3A SLC6A4
22 myocardial infarction 29.3 CYP2C19 GHRL GNB3 PTGS1 PTGS2
23 schizophrenia 29.0 CCK CCKAR GNB3 HRH2 HTR1A HTR3A
24 gastric ulcer 29.0 CXCL8 CYP2C19 HRH2 PTGS1 PTGS2
25 gastrointestinal system disease 28.7 CCK CCKAR CXCL8 GHRL PTGS2 SST
26 opisthorchiasis 11.1
27 angina pectoris 11.0
28 diabetic neuropathy 11.0
29 taeniasis 11.0
30 viral gastritis 11.0
31 bacterial gastritis 11.0
32 helicobacter pylori infection 10.6
33 depression 10.3
34 duodenitis 10.2
35 pylorospasm 10.2 GHRL SST
36 trigeminal neuralgia 10.2 SLC6A4 TRPV1
37 pancreatic steatorrhea 10.2 CCK GHRL
38 opioid abuse 10.2 CCK CCKAR
39 postcholecystectomy syndrome 10.1 CCK SST
40 gastric cancer 10.1
41 hypereosinophilic syndrome 10.1
42 anorexia nervosa 10.1 CCK GHRL SLC6A4
43 heart disease 10.1
44 chronic laryngitis 10.1 CYP2C19 HRH2
45 aspirin resistance 10.1 PTGS1 PTGS2
46 esophageal disease 10.1 HRH2 PTGS2 TRPV1
47 rumination disorder 10.1 HTR1A HTR3A
48 psychosexual disorder 10.1 HTR1A SLC6A4
49 glucose metabolism disease 10.1 GHRL SST TRPV1
50 bulimia nervosa 10.1 CCK GHRL HTR3A SLC6A4

Graphical network of the top 20 diseases related to Dyspepsia:



Diseases related to Dyspepsia

Symptoms & Phenotypes for Dyspepsia

GenomeRNAi Phenotypes related to Dyspepsia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.4 HRH2 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.4 HRH2 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.4 HRH2 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Dyspepsia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 CCK CCKAR GHRL HRH2 HTR1A HTR3A
2 homeostasis/metabolism MP:0005376 9.9 CCK CCKAR GHRL HRH2 HTR1A HTR3A
3 endocrine/exocrine gland MP:0005379 9.86 CCK CCKAR GHRL HRH2 HTR3A PTGS1
4 digestive/alimentary MP:0005381 9.8 CCKAR GHRL HRH2 PTGS1 PTGS2 SST
5 nervous system MP:0003631 9.7 CCK CCKAR GNB3 HRH2 HTR1A HTR3A
6 renal/urinary system MP:0005367 9.1 CCK CCKAR HTR3A PTGS1 PTGS2 TRPV1

Drugs & Therapeutics for Dyspepsia

Drugs for Dyspepsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 483)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
2
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
3
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 51-45-6, 75614-87-8 774
5
Famotidine Approved Phase 4,Phase 3 76824-35-6 3325
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
7
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Not Applicable 102625-70-7 4679
8
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
9
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
11
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
12
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
13
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3, 138530-94-6 9578005
14
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
15
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 1302 156391
16
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
17
Metronidazole Approved Phase 4,Phase 3,Not Applicable 443-48-1 4173
18
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
19
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Not Applicable 50-48-6 2160
20
Cyclobenzaprine Approved Phase 4 303-53-7 2895
21
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
22
Tinidazole Approved, Investigational Phase 4,Phase 2,Phase 3 19387-91-8 5479
23
Tetracycline Approved, Vet_approved Phase 4,Not Applicable 60-54-8 5353990
24
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
25
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 497540 5095
26
Dopamine Approved Phase 4,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
27
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
28
Trimebutine Approved Phase 4 39133-31-8
29
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
30
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
31
Ranitidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 66357-35-5, 66357-59-3 3001055
32
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Not Applicable 21645-51-2
33
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 137-58-6 3676
34
Montelukast Approved Phase 4,Not Applicable 158966-92-8 5281040
35
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 57808-66-9 3151
36
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
37
Licorice Approved Phase 4
38 Hydrotalcite Approved, Experimental, Investigational Phase 4,Not Applicable 12304-65-3
39
Sucralfate Approved Phase 4,Not Applicable 54182-58-0 0
40
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
41
Alginic acid Approved, Investigational Phase 4,Phase 3 9005-32-7
42
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
43
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 447043
44
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2 114-07-8 12560
45
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
46
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
47
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
48
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
49
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 637568 5271565
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 455)
# Name Status NCT ID Phase Drugs
1 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
2 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4 Mirtazapine
3 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
4 The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia Unknown status NCT01608750 Phase 4 Pantoprazol;Folic Acid
5 Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
6 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
7 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
8 Mast Cells in Acid-induced Intestinal Permeability Unknown status NCT02664051 Phase 4 Nalcrom;placebo
9 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
10 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
11 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
12 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
13 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
14 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
15 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
16 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
17 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
18 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
19 Buspirone Plus Omeprazole for Functional Dyspepsia Completed NCT03444831 Phase 4 Buspirone;Placebo Oral Tablet
20 Comparison of Pantoprazole and Ranitidine in Dyspepsia Completed NCT01737840 Phase 4 Pantoprazole;Ranitidine
21 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
22 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
23 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4 Omeprazole;Flupentixol-Melitracen(psychological and GI) + Omeprazole;Flupentixol-Melitracen(psychological) + Omeprazole;Flupentixol-Melitracen(without explanation) + Omeprazole
24 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
25 A Study to Demonstrate the Efficacy and Safety of Motilitone® Completed NCT01817465 Phase 4 Motilitone ®;Pantoline®;Motilitone® and Pantoline®
26 The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study Completed NCT02460601 Phase 4 Qizhiweitong granule
27 A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain Completed NCT02197143 Phase 4 esomeprazole;Ranitidine;hydrotalcid
28 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
29 A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment Completed NCT03635372 Phase 4 Alginate;Sucralfate;Hydrotalcite
30 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
31 Proton Pump Inhibitor Treatment Stop Completed NCT00120315 Phase 4 esomeprazole
32 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
33 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
34 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
35 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole Completed NCT01281501 Phase 4 Normal saline;Pantoprazole;Oral antacid;Hyoscine butylbromide
36 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
37 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
38 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
39 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
40 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
41 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone
42 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
43 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
44 Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis Completed NCT02068482 Phase 4 Rifaximin
45 Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Completed NCT00400400 Phase 4 Enteric-coated mycophenolate sodium (EC-MPS);Mycophenolate mofetil;Placebo to mycophenolate sodium;Placebo to mycophenolate mofetil
46 Tecfidera and the Gut Microbiota Completed NCT02471560 Phase 4 dimethyl fumarate;injectable MS DMT
47 Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation Completed NCT00239005 Phase 4 Enteric-Coated Mycophenolate Sodium (EC-MPS);Mycophenolate Mofetil (MMF)
48 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
49 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
50 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate

Search NIH Clinical Center for Dyspepsia

Cochrane evidence based reviews: dyspepsia

Genetic Tests for Dyspepsia

Anatomical Context for Dyspepsia

MalaCards organs/tissues related to Dyspepsia:

41
Testes, Kidney, Brain, Heart, Colon, Breast, Bone

Publications for Dyspepsia

Articles related to Dyspepsia:

(show top 50) (show all 1472)
# Title Authors Year
1
Association of Low Fecal Elastase-1 and Non-Ulcer Dyspepsia. ( 29914168 )
2018
2
Potential risk factors and prevalence of Helicobacter pylori infection among adult patients with dyspepsia symptoms in Cameroon. ( 29907086 )
2018
3
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
4
Dyspepsia, functional dyspepsia and Rome IV criteria. ( 29900746 )
2018
5
New Medical Approach to Functional Dyspepsia, from Core Symposium 3, Japan Gastroenterological Association 2015-2017. ( 29393229 )
2018
6
Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. ( 29887600 )
2018
7
Editorial on the article A<Factors associated with uninvestigated dyspepsia in students at four Latin American schools of medicine: A multicenter studyA>. ( 29891132 )
2018
8
Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia. ( 29449092 )
2018
9
Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. ( 29392796 )
2018
10
Management of dyspepsia-The role of the emergency department observation unit to optimize patient outcomes. ( 29444751 )
2018
11
Oral Capsaicin Test and Functional Dyspepsia: Any Consideration for Helicobacter pylori Infection and Concomitant Medications? ( 29887603 )
2018
12
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia. ( 29941708 )
2018
13
Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology? ( 29774764 )
2018
14
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial. ( 29938452 )
2018
15
Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. ( 29938463 )
2018
16
Demographic and Clinical Correlates of Mucosal Disaccharidase Deficiencies in Children With Functional Dyspepsia. ( 29762379 )
2018
17
Response to Treatment of <i>Helicobacter pylori</i>-associated Dyspepsia: Eradication of <i>Helicobacter pylori</i> or Correction of Gastric or Intestinal Dysbiosis? ( 29969862 )
2018
18
Burden of impaired sleep quality on work productivity in functional dyspepsia. ( 29774153 )
2018
19
Effect of Zhizhu Kuanzhong capsule on functional dyspepsia: Protocol for a systematic review and meta-analysis of randomized controlled trials. ( 29419664 )
2018
20
Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. ( 29373960 )
2018
21
New insights into functional dyspepsia: further evidence for postprandial distress syndrome as a distinct disease. ( 29396033 )
2018
22
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. ( 29411724 )
2018
23
Fat label compared with fat content: gastrointestinal symptoms and brain activity in functional dyspepsia patients and healthy controls. ( 29924294 )
2018
24
Complementary and alternative treatment in functional dyspepsia. ( 29435308 )
2018
25
Abnormal Gastrointestinal Imaging in a Patient with Dyspepsia. ( 29409878 )
2018
26
Sleep disturbance and psychological distress are associated with functional dyspepsia based on Rome III criteria. ( 29776354 )
2018
27
Effect of miRNA-19a on gastrointestinal motility in rats with functional dyspepsia. ( 29805508 )
2018
28
Electroacupuncture via chronically implanted electrodes improves gastric dysmotility mediated by autonomic-cholinergic mechanisms in a rodent model of functional dyspepsia. ( 29856090 )
2018
29
Time trends in dyspepsia and association with H. pylori and work-related stress-An observational study in white collar employees in 1996 and 2015. ( 29933411 )
2018
30
Helicobacter pylori among patients with uninvestigated dyspepsia: issues to be remembered. ( 29384763 )
2018
31
The effect of Helicobacter pylori eradication on functional dyspepsia in Turkish children. ( 29873438 )
2018
32
Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. ( 29791992 )
2018
33
Mechanism of Action of STWA 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target. ( 29421789 )
2018
34
The association between adult-type hypolactasia and symptoms of functional dyspepsia. ( 29384557 )
2018
35
Uninvestigated dyspepsia and associated factors of patients with gastrointestinal disorders in Dessie Referral Hospital, Northeast Ethiopia. ( 29347978 )
2018
36
Attentional and physiological processing of food images in functional dyspepsia patients: A pilot study. ( 29362408 )
2018
37
Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. ( 29396034 )
2018
38
Rebamipide in Functional and Organic Dyspepsia: Sometimes the Best Offense Is a Good Defense. ( 29464582 )
2018
39
Reassessing the value of gastroscopy for the investigation of dyspepsia. ( 29484162 )
2018
40
Electroacupuncture for patients with refractory functional dyspepsia: A randomized controlled trial. ( 29488274 )
2018
41
Morphological and functional changes of chronic pancreatitis in patients with dyspepsia: A prospective, observational, cross-sectional study. ( 29496438 )
2018
42
Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study). ( 29498457 )
2018
43
Comparison of functional dyspepsia with organic dyspepsia in terms of attachment patterns. ( 29501961 )
2018
44
Systematic review: Disease-specific instruments to assess gastrointestinal symptoms in functional dyspepsia. ( 29520918 )
2018
45
Identification of Individuals with Functional Dyspepsia With a Simple, Minimally Invasive Test: A Single Center Cohort Study of the Oral Capsaicin Test. ( 29533398 )
2018
46
Dyspepsia and Wilkie syndrome, an uncommon cause, but often forgotten. ( 29571726 )
2018
47
Electroacupuncture plus standard of care for managing refractory functional dyspepsia: protocol of a pragmatic trial with economic evaluation. ( 29593017 )
2018
48
Dyspepsia. ( 29596983 )
2018
49
Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation. ( 29599471 )
2018
50
Regional Brain Activity During Rest and Gastric Water Load in Subtypes of Functional Dyspepsia: A Preliminary Brain Functional Magnetic Resonance Imaging Study. ( 29605982 )
2018

Variations for Dyspepsia

Expression for Dyspepsia

Search GEO for disease gene expression data for Dyspepsia.

Pathways for Dyspepsia

Pathways related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 CCK CCKAR CXCL8 GHRL GNB3 HRH2
2 12.27 GNB3 HTR1A PTGS1 PTGS2
3
Show member pathways
11.91 CYP2C19 PTGS1 PTGS2
4
Show member pathways
11.74 GNB3 HTR1A HTR3A
5
Show member pathways
11.7 CYP2C19 PTGS1 PTGS2
6 11.65 CXCL8 GNB3 HTR1A HTR3A SLC6A4 SST
7 11.25 CYP2C19 GNB3 PTGS1
8 11.23 CYP2C19 GNB3 HTR1A HTR3A PTGS1 PTGS2
9 10.99 PTGS1 PTGS2
10
Show member pathways
10.97 PTGS1 PTGS2
11 10.94 HTR1A HTR3A SLC6A4
12 10.89 PTGS1 PTGS2
13 10.86 PTGS1 PTGS2
14 10.71 CXCL8 PTGS1 PTGS2
15 10.58 PTGS1 PTGS2

GO Terms for Dyspepsia

Cellular components related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 CCKAR HRH2 HTR1A HTR3A SLC6A4 TRPV1
2 neuronal cell body GO:0043025 9.56 CCK HTR3A SST TRPV1
3 dendrite GO:0030425 9.35 CCK GNB3 HRH2 HTR1A TRPV1
4 organelle membrane GO:0031090 9.33 CYP2C19 PTGS1 PTGS2
5 neuron projection GO:0043005 9.02 GNB3 HTR3A PTGS2 SLC6A4 TRPV1

Biological processes related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 CCK CXCL8 GHRL SST
2 inflammatory response GO:0006954 9.86 CXCL8 PTGS1 PTGS2 TRPV1
3 chemical synaptic transmission GO:0007268 9.76 HRH2 HTR1A HTR3A SST
4 excitatory postsynaptic potential GO:0060079 9.61 GHRL HTR3A TRPV1
5 decidualization GO:0046697 9.58 GHRL PTGS2
6 regulation of blood pressure GO:0008217 9.58 GNB3 PTGS1 PTGS2
7 prostaglandin metabolic process GO:0006693 9.57 PTGS1 PTGS2
8 cellular response to ATP GO:0071318 9.55 PTGS2 TRPV1
9 vasoconstriction GO:0042310 9.54 HTR1A SLC6A4
10 prostaglandin biosynthetic process GO:0001516 9.52 PTGS1 PTGS2
11 response to organonitrogen compound GO:0010243 9.5 PTGS2 SST TRPV1
12 cyclooxygenase pathway GO:0019371 9.49 PTGS1 PTGS2
13 serotonin receptor signaling pathway GO:0007210 9.48 HTR1A HTR3A
14 digestion GO:0007586 9.43 CCK PGC SST
15 regulation of hormone secretion GO:0046883 9.37 CCKAR HTR1A
16 memory GO:0007613 9.26 CCK HRH2 PTGS2 SLC6A4
17 G protein-coupled receptor signaling pathway GO:0007186 9.23 CCK CCKAR CXCL8 GHRL GNB3 HRH2
18 negative regulation of synaptic transmission, dopaminergic GO:0032227 9.16 PTGS2 SLC6A4
19 signal transduction GO:0007165 10.05 CCK CCKAR CXCL8 GNB3 HRH2 HTR1A

Molecular functions related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.43 CYP2C19 PTGS1 PTGS2
2 hormone activity GO:0005179 9.33 CCK GHRL SST
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2
4 serotonin binding GO:0051378 8.8 HTR1A HTR3A SLC6A4

Sources for Dyspepsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....